Comprehensive medication guide to Valganciclovir including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay for generic valganciclovir on most commercial plans (Tier 2 formulary placement); prior authorization typically required. Medicare Part D covers it with an annual out-of-pocket cap of $2,100 in 2026.
Estimated Cash Pricing
$3,000–$3,400 retail for generic valganciclovir (60 tablets, 450 mg); as low as $90–$130 with GoodRx or SingleCare coupons for a 30-day supply. Brand Valcyte retails for $5,000+ per month.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Valganciclovir (brand name Valcyte) is an oral antiviral medication used to prevent and treat infections caused by cytomegalovirus (CMV), a member of the herpesvirus family. It is a prodrug — meaning it is chemically converted inside the body into its active form, ganciclovir, after you swallow it.
Valganciclovir is FDA-approved for the treatment of CMV retinitis in adults with AIDS, and for the prevention of CMV disease in adults and children after kidney, heart, or kidney-pancreas organ transplants. It is widely used in transplant medicine and HIV/AIDS care as a cornerstone antiviral medication. Generic valganciclovir became available after patent expiration, significantly reducing costs for patients using coupon programs.
Valganciclovir is available as 450 mg film-coated tablets (for adults) and as a 50 mg/mL oral solution (preferred for young children). It is classified as a purine nucleoside analogue and has the drug class designation of CMV nucleoside analogue.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
After oral administration, valganciclovir is rapidly absorbed in the gastrointestinal tract and converted by intestinal and hepatic esterases into ganciclovir — the active drug. This conversion achieves a ganciclovir bioavailability of approximately 60% with food, roughly 10 times higher than oral ganciclovir capsules.
Inside CMV-infected cells, ganciclovir is phosphorylated first by the viral enzyme UL97 kinase (a critical step that makes this drug selectively target infected cells) and then by cellular kinases into ganciclovir triphosphate. This activated form competitively inhibits CMV DNA polymerase (encoded by UL54), blocking viral DNA replication and preventing the virus from making new copies of itself.
Valganciclovir does not cure CMV — it suppresses viral replication. CMV remains in the body in a latent state. This is why transplant patients may take valganciclovir for 100–200 days after transplant, and why CMV can reactivate if therapy is stopped prematurely or immunity wanes.
450 mg — tablet
Film-coated oval tablet; for adults and older children who can swallow tablets. Standard adult dose is 900 mg (2 tablets) once or twice daily depending on indication.
50 mg/mL — oral solution
Reconstituted powder; tutti-frutti flavored; preferred for young children. Refrigerate after mixing; discard after 49 days.
Valganciclovir is not in FDA shortage as of 2026, but it is a specialty drug that most retail pharmacies do not routinely stock. Patients frequently encounter difficulty filling their prescriptions at chain pharmacies, even though national supply is adequate. The drug's high cost (over $3,000 per month at retail) and limited patient population mean that pharmacies prefer to order it on demand rather than keep it on the shelf.
The best sources for valganciclovir are hospital and transplant center pharmacies, specialty pharmacies (Accredo, CVS Specialty, AllianceRx, Optum Rx Specialty), and independent community pharmacies that can special-order within 24–48 hours. Patients in the HIV/AIDS community may also access it through Ryan White-affiliated clinics.
To find which pharmacies near you have valganciclovir in stock, use medfinder — a service that calls pharmacies on your behalf and texts you the results.
Valganciclovir is not a controlled substance, so any licensed U.S. prescriber can write a prescription without special DEA authorization. However, due to the complexity of CMV management and the serious side effects requiring close monitoring, valganciclovir is almost exclusively prescribed by specialists. Insurance prior authorization often requires specialist documentation.
Telehealth availability for valganciclovir is limited to maintenance refills for established, stable patients. New prescriptions and initiation of therapy require in-person evaluation with specialist oversight and baseline lab work.
No. Valganciclovir is not a controlled substance and is not scheduled by the DEA. Any licensed prescriber in the United States — including physicians (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs) — can write a prescription for valganciclovir without any special registration or DEA number for that purpose.
While valganciclovir is not a controlled substance, it is a prescription-only medication with serious FDA boxed warnings for hematologic toxicity (severe bone marrow suppression), teratogenicity (birth defects), and potential carcinogenicity. Its use requires physician oversight, regular laboratory monitoring, and precise dose adjustments based on kidney function. These clinical requirements — not regulatory scheduling — are why it is managed exclusively in specialist settings.
Some insurance plans require prior authorization before covering valganciclovir, which can create temporary access delays. This is an administrative requirement, not a legal restriction on who can prescribe it.
The following side effects occur in at least 20% of adult patients taking valganciclovir in clinical trials:
The FDA has issued multiple boxed warnings for valganciclovir's most serious risks:
Know what you need? Skip the search.
Letermovir (Prevymis)
CMV terminase complex inhibitor; FDA-approved for CMV prophylaxis in adult allogeneic HCT recipients and high-risk kidney transplant recipients. No bone marrow suppression; no cross-resistance with valganciclovir. Not for active CMV treatment.
Ganciclovir (Cytovene IV)
IV formulation; parent drug of valganciclovir. Preferred for severe or life-threatening CMV disease and CMV in stem cell transplant recipients. Not an oral alternative.
Maribavir (Livtencity)
CMV UL97 kinase inhibitor; oral agent approved for CMV infections resistant/refractory to ganciclovir, valganciclovir, foscarnet, or cidofovir in transplant recipients.
Foscarnet (Foscavir)
IV antiviral; for CMV resistant to ganciclovir/valganciclovir or when those agents are contraindicated. Significant nephrotoxicity and electrolyte abnormalities; second-line only.
Cidofovir (Vistide)
IV antiviral; third-line option for ganciclovir-resistant CMV. Highly nephrotoxic; requires co-administration of probenecid and IV saline hydration.
Prefer Valganciclovir? We can find it.
Zidovudine (AZT)
majorBoth drugs suppress bone marrow. Combination significantly increases risk of severe neutropenia and anemia. Close monitoring required; consider alternative antiretroviral.
Mycophenolate mofetil (CellCept)
majorIn renal impairment, both drugs accumulate. Risk of additive bone marrow suppression and kidney toxicity. Monitor CBC and renal function closely.
Imipenem-cilastatin (Primaxin)
majorCase reports of generalized seizures when combined with ganciclovir/valganciclovir. Avoid combination if possible; use alternative carbapenem.
Probenecid
moderateReduces renal tubular secretion of ganciclovir, increasing its blood levels. Monitor for ganciclovir toxicity (increased bone marrow suppression, kidney effects).
Didanosine (ddI)
majorGanciclovir may increase didanosine blood levels. Monitor for didanosine toxicity including pancreatitis. Use alternatives if available.
Cyclosporine
majorBoth nephrotoxic. Combined use increases risk of acute renal failure and elevated valganciclovir blood levels due to reduced clearance.
NSAIDs (ibuprofen, naproxen)
moderateReduce kidney blood flow, impairing ganciclovir clearance and increasing toxicity risk. Transplant patients should generally avoid NSAIDs entirely.
Valganciclovir is a critical medication for immunocompromised patients — whether you are managing CMV risk after an organ transplant or treating active CMV retinitis in the setting of AIDS. It is one of those drugs where access gaps carry real clinical consequences: missed doses can allow CMV to reactivate, leading to organ damage, vision loss, or life-threatening disease.
The good news is that valganciclovir is not in national shortage. The availability challenge is structural — most retail pharmacies don't carry it — and can be solved by connecting with the right pharmacy network (specialty pharmacies, transplant center pharmacies) and planning ahead with 90-day fills and early refills.
Cost is a significant barrier, but coupon programs (GoodRx, SingleCare) reduce generic valganciclovir to $90–$130 per month for uninsured patients. Patient assistance programs exist for brand Valcyte. If you are struggling to find valganciclovir at a pharmacy near you, medfinder calls pharmacies in your area to find which ones can fill your prescription — so you can focus on your health, not on hold music.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini